TY - JOUR
T1 - VEGF in Signaling and Disease
T2 - Beyond Discovery and Development
AU - Apte, Rajendra S.
AU - Chen, Daniel S.
AU - Ferrara, Napoleone
N1 - Funding Information:
This study was supported by NIH grants R01-EY019287-06A1 (R.S.A.), R21-EY026707-02 (R.S.A.), R21-EY028701-01 (N.F.), and P30-EY02687 ; Champalimaud Award (N.F.); Glenn Foundation for Medical Research Award (R.S.A.); Starr Foundation (R.S.A.); Jeffrey Fort Innovation Fund (R.S.A.); Edward N. and Della L. Thome Foundation Award (R.S.A.); and an unrestricted grant from Research to Prevent Blindness , New York, NY to the Department of Ophthalmology, Washington University School of Medicine, St. Louis, MO. The authors would like to thank Mr. Danyel Cavazos for assistance with the illustrations.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/3/7
Y1 - 2019/3/7
N2 - The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our understanding of vasculogenesis and angiogenesis during development and physiological homeostasis. Over a short span of two decades, our understanding of the molecular mechanisms by which VEGF coordinates neurovascular homeostasis has become more sophisticated. The central role of VEGF in the pathogenesis of diverse cancers and blinding eye diseases has also become evident. Elucidation of the molecular regulation of VEGF and the transformative development of multiple therapeutic pathways targeting VEGF directly or indirectly is a powerful case study of how fundamental research can guide innovation and translation. It is also an elegant example of how agnostic discovery and can transform our understanding of human disease. This review will highlight critical nodal points in VEGF biology, including recent developments in immunotherapy for cancer and multitarget approaches in neovascular eye disease. Since it discovery two decades ago, VEGF has emerged as an important modulator of vascular biology, with therapeutics targeting VEGF signaling being central to the treatment of cancer and eye disease.
AB - The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our understanding of vasculogenesis and angiogenesis during development and physiological homeostasis. Over a short span of two decades, our understanding of the molecular mechanisms by which VEGF coordinates neurovascular homeostasis has become more sophisticated. The central role of VEGF in the pathogenesis of diverse cancers and blinding eye diseases has also become evident. Elucidation of the molecular regulation of VEGF and the transformative development of multiple therapeutic pathways targeting VEGF directly or indirectly is a powerful case study of how fundamental research can guide innovation and translation. It is also an elegant example of how agnostic discovery and can transform our understanding of human disease. This review will highlight critical nodal points in VEGF biology, including recent developments in immunotherapy for cancer and multitarget approaches in neovascular eye disease. Since it discovery two decades ago, VEGF has emerged as an important modulator of vascular biology, with therapeutics targeting VEGF signaling being central to the treatment of cancer and eye disease.
UR - http://www.scopus.com/inward/record.url?scp=85060334156&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2019.01.021
DO - 10.1016/j.cell.2019.01.021
M3 - Review article
C2 - 30849371
AN - SCOPUS:85060334156
SN - 0092-8674
VL - 176
SP - 1248
EP - 1264
JO - Cell
JF - Cell
IS - 6
ER -